Flupirtine (FLU) is a non-opioid analgesic drug with no antipyretic or antiphlogistic effects 27 labelled for humans. It does not induce the side effects associated with the classical drugs used as 
human beings [1] . Flupirtine is a centrally acting analgesic with a mechanism of action unlike that 50 of opiates and NSAIDs. It is active with a favourable tolerability and with no antipyretic or 51 antiphlogistic effects in humans [2] . Flupirtine is the first drug to be recognised in the unique class 52 of 'Selective Neuronal Potassium Channel Openers' (SNEPCO) [3] . It interacts with the G-protein- Italy). Deionised water was produced by a Milli-Q Milli-pore Water System (Millipore, MA, USA).
91
All other reagents and materials were of analytical grade and supplied from commercial sources.
92
The LC mobile phase was filtered through 0.2 µm cellulose acetate membrane filters (Sartorius M A N U S C R I P T A C C E P T E D design (2 x 2 Latin-square). All subjects were fasted for 12 h overnight before each experiment.
107
In both periods, a jugular catheter was placed for the purpose of blood sample collection. In criterion. The pharmacokinetic calculations were carried out using WinNonLin v 5.3.1 (Pharsight).
158
The PO bioavailability was calculated from the ratio of the areas under the plasma FLU 159 concentration curve after PO and IV administration, respectively, indexed to their respective dose: 
experiments, differences were considered significant if P < 0.05. 
Results

170
The HPLC method was re-validated using donkey plasma. Briefly, FLU was linear (r 2 >0.99)
171
in the range 10-1500 ng/mL. Limit of detection and quantification were 3 and 10 ng/mL, 172 respectively. When samples exceeded the upper limit of the range, they were re-analysed after 173 appropriate dilution. The intraday repeatability was measured as coefficient of variation and was 174 lower than 4.9 %, whereas accuracy, measured as closeness to the concentration added on the same 175 replicates, was lower than 7.1 %.
177
No behavioral changes or alterations in health parameters were observed in the IV and PO Table 1 .
195
Discussion 196
Flupirtine is a centrally acting, non-opioid analgesic that is available in a number of European Allometric scaling is an approach for dosage selection that can be used in the absence of 212 either species-specific pharmacokinetic data or prior drug experience in the target species [29] . In 213 the present study, an evidence-based approach rather than an allometric calculation of the dose was M A N U S C R I P T
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preferred. Both the approaches share the assumption that species differences in pharmacodynamics 215 are clinically negligible. The oral dose administered in the present study (5 mg/kg) was about 3 216 times higher than the minimum dose reported in human clinical practice (100 mg/subject/day).
217
However, it was still within the recommended human clinical range (100-400 mg/subject/day) [15] .
218
The rationale for oral dose selection of 5 mg/kg was based on earlier preclinical studies in dogs and 
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FLU is not maintained in excess of that plasma level for long. Indeed in both the drug 238 administrations, FLU plasma concentrations are below that value after 1.5 hours.
240
Flupirtine is a water-soluble compound in the form of maleate salt (pKa 5.3) that is rapidly 241 absorbed from the human gastro intestinal tract [36] . The T max found in this study (0.33 h) was 242 shorter than the T max reported for dogs (1.42 h), humans (range 1.6-1.8 h), and cats (2.78 h) The pharmacokinetics of flupirtine in donkeys is different from those earlier reported in cats and dogs
